Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer.

In conclusion, this therapeutic combination represents a promising new precision medicine approach for patients with refractory metastatic WT RAS CRC.
PMID: 32652471 [PubMed - as supplied by publisher]

Source: Translational Oncology - July 7, 2020 Category: Cancer & Oncology Authors: Cohen AS, Geng L, Zhao P, Fu A, Schulte ML, Graves-Deal R, Washington MK, Berlin J, Coffey RJ, Manning HC Tags: Transl Oncol Source Type: research